Patent cliff concerns drive Merck’s $11 billion Prometheus buyout
Deal hoped to stave off investor concerns about expiring patents and diversify product pipeline
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.